Custodio, A <br/><br/>
Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab.  [electronic resource] 

 -  British journal of cancer  Jun 2017 
 - 1526-1535 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Validation Study 
<br/><br/><label>ISSN: </label>1532-1827 
<br/><br/><label>Standard No.: </label>10.1038/bjc.2017.122  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--chemistry<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Ascites--etiology<br/>Bone Neoplasms--secondary<br/>Esophageal Neoplasms--chemistry<br/>Esophagogastric Junction<br/>Health Status<br/>Humans<br/>Lymphocyte Count<br/>Middle Aged<br/>Neoplasm Grading<br/>Neutrophils<br/>Nomograms<br/>Receptor, ErbB-2--analysis<br/>Stomach Neoplasms--chemistry<br/>Survival Rate<br/>Trastuzumab--administration & dosage<br/>Tumor Burden<br/>White People<br/>Young Adult